Efficacy and Safety of Tralokinumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results of the Phase 3 ECZTRA 6 Trial

Amy Paller, Andrew Blauvelt, Weily Soong, Shinichi Imafuku, Chih-ho Hong, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson Lophaven, Marie L.A. Schuttelaar, Petra Amoudruz, Azra Kurbasic, Lise Soldbro, Katja Lophaven, Michael Cork, Anthony Bewley, Eric L. Simpson

¹Feinberg School of Medicine, Northwestern University, Chicago IL, USA; ²Oregon Medical Research Center, Portland, OR, USA; ³Allervie Health-Alabama Allergy & Asthma Center, Birmingham, AL, USA; ⁴Fukuoka University of British Columbia, Vancouver, BC, Canada; ⁶University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands; ⁷LEO Pharma A/S, Ballerup, Denmark; ⁸University of Sheffield, UK; ⁹Barts Health NHS Trust, London, UK; ¹⁰Oregon Health & Science University, Portland, OR, USA

Introduction

- Atopic dermatitis (AD) is a chronic, pruritic, inflammatory skin disease that can negatively impact quality of life in adolescents¹
- Negative impacts of AD include effects on school performance, social relationships, participation in sports and increased rates of anxiety, depression, and suicidal ideation²⁻⁴
- Tralokinumab is a fully human, high-affinity, monoclonal antibody that specifically neutralizes interleukin (IL)–13, a key driver of skin barrier dysfunction, inflammation and dysbiosis in AD⁵⁻⁹
- In adult phase 3 trials, tralokinumab demonstrated efficacy and safety for treatment of AD^{10, 11}

Objective

To evaluate the efficacy and safety of tralokinumab in adolescents with moderate-to-severe AD in the phase 3 ECZTRA 6 trial (NCT03526861)


Methods

Study design (Figure 1)

- Adolescent patients were randomized 1:1:1 to subcutaneous tralokinumab 150 mg or 300 mg every 2 weeks (Q2W), or placebo for an initial treatment period of 16 weeks
- Primary endpoints were Investigator's Global Assessment (IGA) score 0/1 and ≥75% improvement in Eczema
 Area and Severity Index (EASI-75) at Week 16
- Patients achieving primary endpoints without rescue treatment were re-randomized to tralokinumab Q2W or every 4 weeks (Q4W), at their same initial dosage for 36 weeks of maintenance treatment as shown in Figure 1
- Patients not achieving primary endpoints at Week 16, those receiving rescue treatment from Week 2 to Week 16, and those meeting other specific criteria[†] were transferred to open-label treatment of tralokinumab 300 mg Q2W plus optional mild-to-moderate strength topical corticosteroids (TCS)

Key inclusion criteria

- Age 12 17
- History of AD for ≥1 year
- BSA involvement ≥10% at screening and baseline
- EASI score ≥12 at screening and ≥16 at baseline
- IGA score ≥3 at screening and baseline
- History of TCS and/or topical calcineurin inhibitor treatment failure, or subjects for whom these treatments are medically inadvisable
- Stable dose of emollient ≥2 times daily for ≥14 days before randomization



*loading dose of 600 mg for patients receiving 300 mg Q2W or 300 mg for those receiving 150 mg Q2W

†Patients not achieving EASI-75 over ≥4 weeks with IGA ≥2 after IGA=0 at Week 16, or with IGA ≥3 after IGA=1 at Week 16, or who had IGA >1 at Week 16; patients who receive rescue treatment after Week 16

AD, atopic dermatitis; EASI, Eczema Area and Severity Index; IGA, Investigator's Global Assessment; Q2W, every 2 weeks; Q4W, every 4 weeks; TCS, topical corticosteroids.

Statistical analyses and endpoints

- EASI-75, IGA 0/1, and secondary endpoint ≥4-point improvement in adolescent pruritus Numerical Rating Scale (NRS) were analyzed using Cochran-Mantel-Haenszel test stratified by geographic region and baseline disease severity
- Patients receiving rescue therapy between Week 2 and 16 or with missing data at Week 16 were considered non-responders
- Secondary endpoints, change from baseline in SCORing AD (SCORAD) and Children's Dermatology Life Quality
 Index (CDLQI) were analyzed using a linear mixed model for repeated measurements
- Data after use of rescue or discontinuation were disregarded
- A closed testing procedure with hierarchical tests, alpha splitting, and alpha recycling were applied for above efficacy endpoints
- The safety population was defined as all randomized patients who received ≥1 injection of study drug

Results

Patient characteristics

Baseline demographic and clinical characteristics were comparable across treatment groups (Table 1)


	Placebo (N=94)	Tralokinumab 150 mg Q2W (N=98)	Tralokinumab 300 mg Q2W (N=97)
Mean age, years	14.3	14.8	14.6
Age group, n (%)			
12-14	49 (52.1)	37 (37.8)	45 (46.4)
15–17	45 (47.9)	61 (62.2)	52 (53.6)
Male, n (%)	51 (54.3)	51 (52.0)	47 (48.5)
Race/Ethnicity, n (%)			
White	53 (56.4)	55 (56.1)	56 (57.7)
Black or African American	11 (11.7)	7 (7.1)	14 (14.4)
Asian	23 (24.5)	28 (28.6)	20 (20.6)
Hispanic or Latino	6 (6.4)	10 (10.2)	9 (9.3)
Mean duration of AD, years (SD)	12.7 (3.7)	12.1 (3.7)	12.1 (3.5)
Mean BSA involvement with AD, % (SD)	51.4 (23.9)	52.4 (22.6)	49.6 (23.3)
Severe disease (IGA=4), n (%)	43 (45.7)	44 (44.9)	48 (49.5)
EASI, mean score (SD)	31.2 (14.5)	32.1 (12.9)	31.8 (13.9)
SCORAD, mean score (SD)	67.4 (14.9)	67.7 (14.4)	68.3 (13.7)
CDLQI, mean score (SD)	13.3 (6.0)	12.9 (6.3)	13.4 (7.3)
Worst daily pruritus NRS, mean weekly score (SD)	7.5 (1.7)	7.5 (1.6)	7.8 (1.5)

BSA: Body surface area. AD: Atopic Dermatitis. n: Number of subjects in analysis set. Q2W: Every 2 weeks. IGA: Investigator's Global Assessment. EASI: Eczema Area and Severity Index. SCORAD: Scoring Atopic Dermatitis. CDLQI: Children's Dermatology Life Quality Index. NRS: Numeric rating scale.

Week 16 efficacy analyses

- At Week 16, a significantly greater proportions of patients receiving tralokinumab achieved the primary endpoints of IGA 0/1 and EASI-75 without use of rescue compared to those receiving placebo (Figures 2A, B)
- A significantly greater proportions of patients receiving tralokinumab vs placebo achieved ≥4-point improvement in adolescent pruritus NRS at Week 16 without use of rescue (Figure 2C)
- Tralokinumab treatment was associated with greater improvement than placebo in SCORAD and CDLQI from baseline to Week 16 (Figures 2D, E)


Figure 2. Tralokinumab treatment demonstrated efficacy vs placebo across endpoints at Week 16. A. IGA 0/1 B. EASI-75 C. ≥4-point improvement in adolescent pruritus NRS D. Change in SCORAD E. Change in CDLQI



Q2W: Every 2 weeks. IGA: Investigator's Global Assessment. EASI: Eczema Area and Severity Index. NRS: Numeric rating scale. SCORAD: Scoring Atopic Dermatitis. CDLQI: Children's Dermatology Life Quality Index.

Safety through Week 16

- Through Week 16, percentages of adverse events (AEs), serious AEs, AEs leading to discontinuation, and conjunctivitis events were similar between the tralokinumab (150 mg/300 mg) and placebo treatment groups (Table 2)
- The majority of AEs in all treatment groups were mild or moderate in severity and subjects recovered from most of the AEs



Conclusions

- At Week 16, tralokinumab 150 mg and 300 mg Q2W demonstrated significant efficacy vs placebo across primary and secondary endpoints in adolescents with moderate-to-severe AD
- Tralokinumab was well tolerated; efficacy and safety profiles were comparable to those in phase 3
 adult tralokinumab trials

Reference

1. Marciniak J, et al. *Acta Derm Venereol*. 2017;97:711–714; **2.** Ricci G, et al. *Dermatol Reports*. 2011;4; **3.** Slattery M, et al. *J Allergy Clin Immunol*. 2011; 128:668–671; **4.** Halvorsen JA, et al. *J Invest Dermatol*. 2014;134:1847–1854; **5.** Bieber T. *Allergy*. 2020;75:54–62; **6.** Furue K, et al. *Immunology*. 2019; 158:281–286; **7.** Szegedi K, et al. *J Eur Acad Venerol Dermatol*. 2015;29:2136–2144; **8.** Tsoi LC, et al. *J Invest Dermatol*. 2019;139: 1480–1489; **9.** Popovic B, et al. *J Mol Biol*. 2017;429: 208–219; **10.** Wollenberg A, et al. *Br J Dermatol*. 2021;184:437–449; **11.** Silverberg JI, et al. *Br J Dermatol*. 2021; 184:450–463.

Disclosures Amy Paller has served as an investigator for AbbVie, Anaptysbio, Incyte, Janssen, KrystalBio, LEO Pharma, Regeneron, and UCB, received honorarium for consultancy from AbbVie,

Regeneron, Sanofi Genzyme, Seanergy, and UCB, and served on a Data Safety Monitory Board for AbbVie, Bausch, Galderma, and Novan. Andrew Blauvelt is a scientific adviser and clinical study investigator for AbbVie, Abcentra, Aligos, Almirall, Amgen, Arcutis, Arena, Aslan, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly, Evommune, Forte, Galderma, Incyte, Janssen, Landos, LEO Pharma, Novartis, Pfizer, Rapt, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, Sun Pharma, UCB Pharma Weily Soong has served on the advisory board and received research grants from Abbvie, LEO, Genentech, Inc., Teva, Novartis, and Pfizer; served on the advisory board, received research grants, and was a speaker for Amgen, AstraZeneca, Regeneron, Sanofi, and GlaxoSmithKline; received research grants and was a speaker for Optinose; received research grants from Aimmune, Avillion, Galderma, Gossamer Bio, 3M, and LEO Pharma. Shinichi Imafuku is a researcher, consultant, or speaker for Abbvie, Amgen, Celgene, DaiichiSankyo Eisai, KyowaKirin, Lilly, Taihoyakuhinkogyo, TanabeMitsubishi, Tsumura, Torii, Maruho, Novartis, LEO Pharma and Janssen. Chih-ho Hong is a researcher, consultant, and/or advisor for AbbVie, Amgen, Arcutis, Bausch Health, Boehringer Ingelheim, Celgene, Dermavant, Dermira, DS Biopharma, Galderma, GlaxoSmithKline, Incyte, Janssen, LEO Pharma, Lilly MedImmune, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, and UCB. Marie L.A. Schuttelaar has served on advisory boards for Sanofi Genzyme, Pfizer, LEO Pharma, Eli Lilly, Galderma, and Abbvie; as an investigator for AbbVie, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme, and Galderma; as a consultant for Regeneron Pharmaceuticals, Inc.; has received research grants from Sanofi Genzyme and Novartis. Petra Amoudruz, Azra Kurbasic, Lise Soldbro and Katja Lophaven are employees of LEO Pharma A/S. Michael Cork has served as a clinical trial investigator for Astellas, Galapagos, Johnson & Johnson, LEO Pharma, La Roche-Posay, MSD, Novartis, Perrigo, Regeneron, Sanofi Genzyme, and Stiefel; has served as an advisory board member, consultant, and/or invited lecturer for Pfizer Inc., Amgen, Astellas, Bayer, Johnson & Johnson, LEO Pharma, L'Oréal, MSD, Novartis, Regeneron, Sanofi Genzyme, Stiefel, and Unilever; has received honoraria from Astellas, Johnson & Johnson, LEO Pharma, Novartis, Regeneron, Sanofi Genzyme, and Stiefel; and has received research funding from Bayer. Anthony Bewley has been a consultant for and received consultancy fees or travel bursaries from AbbVie, Almiral, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Sanofi and UCB Pharma. Eric Simpson is a consultant and investigator for Regeneron/Sanofi, Dermira, Menlo Pharmaceuticals, Lilly, Abbvie, Genentech, Medimmune, GSK, LEO Pharma, Celgene, and Pfizer.

Abeona, Almirall, Anaptysbio, Arena, Azitra, BiomX, Boehringer Ingelheim, Castle Biosciences, Catawba, Dermira, Exicure, Forté, Kamari, LEO Pharma, Lillv. LifeMax. Novartis. Pfizer.

Acknowledgments The ECZTRA 6 trial was sponsored by LEO Pharma A/S, Ballerup, Denmark. Originally Presented at Fall Clinical Dermatology Conference, Oct 21-24, 2021